PinPointe USA, Inc. (PinPointe USA) has appointed Bob H. Katz as president and chief executive officer (CEO), and as a member of its board of directors. Katz has twenty-five years of medical device development experience. His experience includes the development of numerous therapeutic and interventional technologies in a wide range of applications.
Prior to joining PinPointe USA, he was president & CEO of Aptus Endosystems, Inc. Katz previously held executive management positions for other medical device companies including president of ZOLL Circulation and Symphonix Devices.
The addition of Katz to the PinPointe USA team is the latest in a series of positive developments for the company, which announced in June the launch of a major North American multi-center clinical trial to evaluate the PinPointe FootLaser, the company’s flagship product for the treatment of onychomycosis and the announcement in February of the company’s receipt of a CE Mark, and in July for TGA approval, for the PinPointe FootLaser opening the way for commercial product launch for the treatment of onychomycosis throughout the EU and Australia.
“We are excited to have Bob join the team and lead our company as we accelerate commercialization of our proprietary laser treatment technology,” said John Strisower, founder and chairman of the board of PinPointe USA. “His breadth of experience in bringing a broad range of medical technologies and products to market will add significant value to the company.”
“This is a very exciting time for the company. We are embarking upon multiple initiatives to build our franchise and establish PinPointe USA as the global leader in onychomycosis treatment,” added Mr. Katz.
Founded in 2004, PinPointe USA is a privately held medical technology company with headquarters in Chico, California.